The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yes if £200 mil as was spoken back in the day based on 190 million shares we were expecting anything up to £1 so with 20 times less shares we should be expecting £20 so circa €26 not $2.6. So it should jump from here those two 100 trades at €2.5 and $3 may prove to be a bit of a bargain. Think the company will be worth more than $28.5 million if this product is indeed better than the market leader which someone paid €billions for. !!!
This sell off is way over done. Nearly 50% of the value of the business has been wiped off since they announced a really good set of H1 results. And this is a year that the biggest contract the company has ever won has started with $1.83 million minimum revenue over a 2 year period. Optimal platform library is due to launch anytime soon with expected revenue in the new financial year which starts on 1/4/22. Crazy crazy value on a company with circa £5 million revenue that will be profitable if it didn’t continue with research and development.
It’s clearly happening but not listing yet. I’m still hoping it gets sold and we just get cash.
It’s crazy to think the only reason the share price is down here at 65/67 is because the market makers have moved it to this level as a function of dealing with the shareholders selling shares against dealing with anyone buying shares, Yet it is still the same company, that is trading the same making drugs just the same and with exactly the same prospects now as they were when those shares were changing hands at when that was £1 or £1.50 or £2 or £2.50.
The price of a company is purely set by the current balance of sellers and buyers. At the current price that the market makers are saying it is at the moment in time.
If all of a sudden there was a lot more people wanting to buy the same companies shares today than who want to sell today then the price would dramatically be changed by those same Market makers to a higher price and it could settle at £1.50 or £2 or higher depending on what equilibrium price was needed to reflect the situation where the buyers and sellers was in balance.
As time has passed new investors need to study the information or be made aware what the prospects are. This is why it’s so important that there is info available from the company to help those buyers and sellers make a judgement of is it good value or bad value at the current price those same market makers are stating on the screens.
Now clearly there are other factors that can change that sentiment. But in essence that’s how shares are valued.
So we all need to accept that.
Now as Ryan has said after his discussions and his assessment of the company he believes this price is a major major opportunity to buy rather than sell.
But still either the market makers want to keep it lower or there are more sellers selling at this price than buying at That price.
So until we get more information to appraise the perceived value to current price the only thing that will change the price is the balance of buyers and sellers.
I know it’s staying the bleeding obvious but thought it might be good for thought.
Can?t get my head around it. Company is really going places with its state of the art new technology will help create humanised antibodies with out need for animals.
It?s a game changer.
Yet no one knows about it other than the long term investors.
The company are sitting on a gold mine and no one knows about it.
OptiMAL will be a sequence generated library with more antibodies than stars in heavens to allow the selection of the perfect antibody drug candidate .
We need to stop hiding our scientific light under a bushel and PR and tell the world what we are developing ASAP
This is a great little business. More investors should Get on board
OptiMAL will be a sequence generated library with more antibodies than stars in heavens to allow the selection of the perfect antibody drug candidate .
We need to stop hiding our scientific light under a bushel and PR and tell the world what we are developing ASAP
This is a great little business. More investors should Get on board
Distributor Manager x2
Cell Line development Team Leader
Senior Laboratory Technician
This is written in the job advert which indicates they are ready for launch planning for Optimal
All reads very well.
Fusion is at a key value inflection point in the Company’s evolution with a key focus on expanding/driving current commercial performance and accessing additional value generating opportunities as well as launch preparations for the new service offerings. Fusion operates in a highly competitive and fast evolving market and in light of this the position for Cell line development team (CLD) leader has become available to grow and develop the CLD department within Fusion Antibodies.
Open advice to the board.
Please can you make a big effort this year to start to improve communication with your shareholders.
Please engage with us and start to tell us the story about what Fusion Antibodies is all about and where you are taking it.
You have a great business don?t be so shy about telling us all how good it is.
Can anyone explain why the Accustem great market in the states is still trading at the same level when they have now completed the 20-1 reduction it should be trading at 20 times higher price surely.
Can’t actually understand what they are trading.
https://www.qub.ac.uk/research-centres/cancer-research/News/QUEENSRESEARCHERSDEVELOPNEWTREATMENTFORPANCREATICCANCER.html
I am sure we are going to here more about pancreatic cancer soon
RNS Number : 2814U
Fusion Antibodies PLC
02 December 2021
Fusion Antibodies plc
("Fusion" or the "Company")
Update on R&D
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces an update to its research and development catalogue following on from the emergence of the new SARS-CoV-2 variant, B.1.1.529 ("Omicron"). The data on Omicron was added to the Global Initiative on Sharing All Influenza Data ("GISAID") archive on 22 November 2021. GISAID is an existing platform for sharing influenza virus sequences and primary information.
In response to the World Health Organisation (WHO) designating Omicron as a "Variant of Concern", Fusion is developing receptor-binding domain ("RBD") antigens as part of the Northern Ireland Coronavirus Antibody Development Alliance (NICADA). The Company has decided to include O micron RBD, alongside the alpha, beta, gamma and delta+ RBD variants, in its development programme with the aim of producing virus-neutralising antibodies. Whilst there can be no guarantee as to the outcome of the inclusion of Omicron in the development programme, if successful, these state-of-the-art antibodies would have affinity to the Omicron RBD and therefore potential neutralisation ability, while also aiding diagnostic testing efforts.
Dr Richard Buick, Chief Scientific Officer at Fusion Antibodies said: "We have decided to try to progress this opportunity given the appearance of the Omicron variant, although we must stress that this is in the very early stages of conception, and we do not have any guarantees in terms of effectiveness or durability. Omicron has many mutations in the RBD region of the spike protein, and these mutations could help the virus evade the body's immune response and make it more transmissible.
"However, by leveraging our experience in developing antibodies against the previous SARS-CoV-2 variants, we would hope that the development of an Omicron RBD-binding antibody could potentially be much accelerated in comparison to previous variants. We are conscious that the fight against COVID-19 is a worldwide effort and as such we are happy to announce our decision to make these proteins available for research and development purposes."
Enquiries:
F
This is very old news Medella went bust but I believe we carried on and made the antibody. So may have news about that one day.
You never know with this secretive little business
Fusion Antibodies Ltd are pleased to announce the in-licensing of the anti-AM2R monoclonal antibody from Medella Therapeutics, to use our CDRx™ humanization technology to develop it as a novel 1st in class therapy for serious cancers with an unmet clinical need.
This is why FAB is going to be a great investment opportunity.
It’s all about discovery and AI diagnostics.
Building a very valuable asset in its Optimal Antibody platform.
Good read. And watch.
https://www.linkedin.com/posts/roche_power-of-diagnostics-activity-6864232254357475328-h_oM
https://www.linkedin.com/posts/edna-d-souza-phd-80646416_department-for-international-trade-dit-activity-6867379822910324736-MFcs
Getting good support feom the department of trade and industry.
Nice.
Wakey wakey investors.
Nothing whatsoever has changed Re the Accustem asset other than the company has been in limbo re any listing or ability to trade the shares in the business
The asset is still the same as it was when explained 20 months ago. It is still presumably 40%!better than the lead product on the market.
All that has transpired is a complete **** storm at trying to dissolve the asset from the Tiziana business and list it in the Nasdaq. Nothing whatsoever has changed with the technology.
What would you have done differently if you were in charge.